Ocuphire Pharma

Pipeline Analysis Reveals 20+ Therapies in Development for Open-Angle Glaucoma Treatment

a month ago

• DelveInsight's latest report identifies 18+ companies developing 20+ therapeutic candidates for open-angle glaucoma, with several treatments advancing through late-stage clinical trials. • Key players including Nicox, Qlaris Bio, and Glaukos Corporation are making significant progress with innovative treatments like NCX 470, QLS-111, and iDose TREX, demonstrating positive clinical outcomes. • Novel drug delivery mechanisms, including sustained-release implants and encapsulated cell therapies, are emerging as promising approaches to address the challenges of treatment adherence and efficacy in glaucoma management.

Ocular Hypertension: Over 60 Companies Advance Clinical Trial Pipeline

4 months ago

• The ocular hypertension market is expanding due to increased prevalence of conditions affecting aqueous humor outflow, leading to elevated intraocular pressure (IOP). • Advancements like sustained-release implants and micro-dosing technologies are enhancing patient compliance and improving outcomes in ocular hypertension treatment. • Enhanced imaging techniques, such as optical coherence tomography (OCT), facilitate early diagnosis and intervention, contributing to the growth of the ocular hypertension market. • Over 60 companies are actively developing more than 70 pipeline drugs for ocular hypertension, signaling robust innovation and future growth potential in the domain.

Global Diabetic Retinopathy Clinical Trials Landscape Analysis Reveals Key Research Trends for 2024

4 months ago

• A comprehensive analysis of global diabetic retinopathy clinical trials has been released, offering insights into trial distribution across G7 and E7 countries and various research phases. • The report highlights significant trends in trial enrollment patterns over the past five years, providing valuable data for healthcare stakeholders and pharmaceutical companies. • The analysis covers detailed assessment of trial statuses, sponsor types, and endpoint evaluations, helping identify key opportunities and challenges in diabetic retinopathy research.

Advancements in Clinical Trials for Fabry Disease, C. difficile Infections, and Mydriasis

6 months ago

• Clinical trials are actively progressing for Fabry Disease, with companies like Idorsia and Sanofi Genzyme developing novel therapies. • Emerging treatments like Venglustat and Pegunigalsidase alfa are expected to significantly impact the Fabry Disease market in the coming years. • Research and development efforts are also focused on Clostridium Difficile Infections, with Vedanta Biosciences leading Phase 3 trials for VE303. • Mydriasis treatments are advancing, with companies like Eyenovia exploring solutions like MYDCOMBI for pupil dilation.

LENZ Therapeutics' LNZ100 NDA Accepted by FDA for Presbyopia Treatment

7 months ago

• The FDA has accepted the New Drug Application (NDA) for LENZ Therapeutics' LNZ100, a potential treatment for presbyopia. • The NDA is supported by Phase 3 CLARITY study data, which demonstrated significant near vision improvement in participants. • Participants in the CLARITY study achieved at least a 3-line improvement in Best Corrected Distance Visual Acuity at near without losing distance visual acuity.

Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline for Inherited Retinal Diseases

7 months ago

• Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, with the combined company renamed Opus Genetics, Inc., focusing on inherited retinal diseases. • The acquisition expands the pipeline to include AAV-based gene therapies for IRDs and phentolamine ophthalmic solution for presbyopia, while seeking a partner for diabetic retinopathy program. • OPGx-LCA5, a gene therapy for LCA5, shows promising early Phase 1/2 data with visual improvements in patients, and pediatric enrollment is expected in early 2025. • The merger extends the company's cash runway into 2026, anticipating key clinical milestones, including data readouts from multiple Phase 1/2 and Phase 3 trials.

Phentolamine Ophthalmic Solution (Ryzumvi) Demonstrates Efficacy in Reversing Mydriasis in Phase 3 Trials

8 months ago

• Phentolamine ophthalmic solution 0.75% (Ryzumvi) significantly reversed pharmacologically-induced mydriasis in MIRA-2 and MIRA-3 Phase 3 trials. • A statistically significant percentage of subjects achieved mydriasis reversal at 90 minutes compared to placebo (p < 0.0001) in both trials. • The solution exhibited a favorable safety profile, with mild and transient adverse events, offering faster recovery from mydriasis. • Ryzumvi, already FDA-approved for mydriasis, is also being evaluated for presbyopia and dim light vision disturbances.

Ocuphire Pharma Initiates Phase 3 Trial of Phentolamine Ophthalmic Solution for Presbyopia

8 months ago

• Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia. • Phentolamine ophthalmic solution 0.75% is under development as a non-invasive alternative to traditional presbyopia treatments. • The VEGA-3 trial (NCT06542497) aims to assess the efficacy and safety of this novel ophthalmic solution.

Ocuphire Pharma Initiates Phase 3 VEGA-3 Trial of Phentolamine Ophthalmic Solution for Presbyopia

9 months ago

• Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia. • The VEGA-3 trial is a randomized, double-masked, placebo-controlled study involving 545 participants, with top-line data expected in 2025. • Phentolamine ophthalmic solution 0.75% aims to provide a non-invasive alternative to traditional corrective measures for presbyopia. • Ocuphire anticipates using VEGA-3 data to support a supplemental New Drug Application with the FDA.